药明康德2019-12-26 12:19
▎医药观澜/报道
今日,精准医疗企业索元生物宣布,其已与Rumpus Therapeutics签订了开发DB102(enzastaurin)用于治疗特定适应症的授权许可协议,后者将获得DB102在肿瘤、肺动脉高压等索元生物核心领域外某些遗传病领域的研发及商业化许可。根据协议,Rumpus Therapeutics将向索元生物支付包...查看全文
牛唐2019-11-25 17:50
$Sunesis制药(SNSS)$ 计划在ASH上发布数据,目前价格低于现金价,上个交易日放量,大概率会来一波。
$百济神州(BGNE)$ $Arqule(ARQL)$查看全文
牛唐2019-07-16 16:31
$Sunesis制药(SNSS)$ Aisling Capital认购了250万股的增发,总持仓达到1000多万股,继续押注BTK$百济神州(BGNE)$ $Arqule(ARQL)$查看全文
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014032 Size: 10 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014022 Size: 5 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014015 Size: 5 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014007 Size: 12 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014010 Size: 5 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014004 Size: 13 KB 网页链接
$Sunesis制药(SNSS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-21-014000 Size: 11 KB 网页链接
$Sunesis制药(SNSS)$ 8-K Current report, items 2.01, 3.03, 5.01, 5.02, 5.03, 8.01, and 9.01 Accession Number: 0001193125-21-054723 Act: 34 Size: 91 KB 网页链接
$Sunesis制药(SNSS)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001564590-21-007784 Act: 34 Size: 8 MB 网页链接
$Sunesis制药(SNSS)$ 8-K Current report, items 5.02 and 5.07 Accession Number: 0001564590-21-007255 Act: 34 Size: 70 KB 网页链接